Ovarian cancer is asymptomatic in early stages and has a poor prognosis once it has received an advanced stage. Delivery of chemotherapeutic agents in a localized manner can provide for treatment especially of drug-resistant forms of ovarian cancer. Researchers at Chungbuk National University, University of Oklahoma, Sookmyung Women’s University, and CTCBIO Inc. used mPEG-DMAEMA (AO019) from PolySciTech Division of Akina, Inc. (www.polyscitech.com) to create thermogel solution for delivery of paclitaxel and olaparib. This research holds promise to improve treatment of ovarian cancer. Read more: Jo, Min Jeong, Moon Sup Yoon, Seo Yeon Kim, Jae Min Lee, Su Jeong Kang, Chun-Woong Park, Jin-Seok Kim, Je-Hyun Yoon, and Dae Hwan Shin. "A combination formulation of TPGS micelles loaded with paclitaxel and olaparib and a pH-thermosensitive hydrogel for treating peritoneal metastasis and drug-resistant ovarian cancer." Journal of Pharmaceutical Investigation (2025): 1-17. https://link.springer.com/article/10.1007/s40005-024-00705-7
“Purpose: Ovarian cancer (OC) is difficult to detect early; therefore, it is highly likely to advance to peritoneal metastasis at the time of diagnosis. Moreover, multi-drug resistance (MDR) results in a high recurrence rate. To address these issues, the present study aimed to design an intraperitoneally administered formulation combining a d-α-tocopherol polyethylene glycol 1000 succinate (TPGS) micelles loaded with paclitaxel (PTX) and olaparib (OLA) and a pH-thermosensitive hydrogel. Methods: To assess PTX and OLA’s synergistic effects, we evaluated the combination index (CI) at various molar ratios and physicochemical properties of the formulations and carried out both in vitro and in vivo experiments. Results: PTX and OLA showed a synergistic effect at all ratios, and considering the various physicochemical properties, a 1:4 ratio using 50 mg of TPGS and a gel polymer concentration of 12.5% w/v was identified as the optimum formulation. In vitro cytotoxicity and cellular uptake assays demonstrated high cytotoxicity of the TPGS micelles compared to those of the free drug and methoxy-poly(ethylene glycol)-poly(ε-caprolactone) (mPEG-PCL) micelles (control) in all formulation groups; TPGS micelles also increased cellular uptake efficiency. Drug release profiles in vitro demonstrated that both PTX and OLA had a release pattern influenced by pH levels, with the slowest release observed at pH 7.4. In vitro and in vivo drug release profiles showed similar release patterns, with PTX showing slower release than OLA. Conclusion: The final formulation of this study represents a promising therapeutic strategy for OC; however, due to potential toxicity issues of the polymer, its clinical application needs to be further studied.”
PDMAEMA-PEG (Cat# AO019): https://akinainc.com/polyscitech/products/polyvivo/index.php?highlight=AO019#h
NEW: Corbion Purasorb® Polymers: https://akinainc.com/polyscitech/products/purasorb/
NEW: Ashland-TM Polymer Products: https://akinainc.com/polyscitech/products/ashland/
No comments:
Post a Comment